942PD - Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179

Ana Oaknin ,K Longauer,I Vergote,A Sahbi,Alexandra Leary ,Izolda Franjkovic ,Els Van Nieuwenhuysen ,Florian Heil ,V Rodriguez Freixinós ,Philippe Toussaint ,Simona Rossomanno ,Lorena Fariñas‐Madrid ,Angelika Lahr ,Nicole Concin ,Tapan K Nayak ,Christophe Boetsch ,Isabelle Ray‐Coquard ,Peter Arne Gerber ,Christophe Massard ,Oliver Krieter

doi:10.1093/annonc/mdx372.012

942PD - Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179

Ana Oaknin , K Longauer + Show 18 more

Open Access

https://doi.org/10.1093/annonc/mdx372.012

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2017
Citations: 6	License type: elsevier-specific: oa user license

Affiliation: Vall d'Hebron Hospital Universitari, Roche (Switzerland), Roche (United Kingdom), Institut Gustave Roussy, Roche (Germany), Claude Bernard University Lyon 1

#Vanucizumab #Platinum-resistant Recurrent Ovarian Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

942PD - Vanucizumab (VAN) in combination with atezolizumab (ATEZO) for platinum-resistant recurrent ovarian cancer (PROC): Results from a single arm extension phase of the phase I study BP28179

Full Text